Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications

Creative Bio-Peptides Awarded $5.78 from NIH to Develop Breakthrough Treatments for Neuroinflammatory/Neurodegenerative Indications

Creative Bio-Peptides, Inc., an emerging drug development company focused on the development of leading-edge multi-chemokine antagonist therapeutic peptides for neuroinflammatory/neurodegenerative conditions, has been awarded $5.8M in non-dilutive funding from three NIH agencies. ...  Read more

PSOMAGEN, INC. IS PARTNERING WITH OLINK PROTEOMICS, ENABLING UNPRECEDENTED MULTI-OMICS CLINICAL STUDIES

PSOMAGEN, INC. IS PARTNERING WITH OLINK PROTEOMICS, ENABLING UNPRECEDENTED MULTI-OMICS CLINICAL STUDIES

ROCKVILLE, Md. — November 11, 2021 — Psomagen, Inc., a North American sequencing-based contract laboratory service and data analysis provider with both CLIA-certified and CAP-accredited facilities, has partnered with Olink Proteomics, which offers an innovative DNA-coupled immunoassay that identifies and quantifies protein biomarkers in clinical samples. The partnership enables end-to-end multi-omics clinical studies, a step that will enable a whole new generation of precision therapies derived from a more robust knowledge of human biology. ...  Read more

BioFactura’s Remarkable Journey

BioFactura’s Remarkable Journey

BioFactura, a leading developer and manufacturer of biosimilars and biodefense products, is one of the crown jewels of Frederick, Maryland’s growing biotech hub. The company is thriving and has secured strong funding from both private and government sources that see the potential of the company’s StableFast™ biosimilars platform. In May 2021, BioFactura reached an important milestone, announcing that it had moved its first biosimilar product into the clinic...  Read more

Immunomic Therapeutics Announces Collaboration With iOncologi

Immunomic Therapeutics Announces Collaboration With iOncologi

November 23, 2021 06:41 PM Eastern Standard Time

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid immunotherapy platform, announced today an exclusive option to license or acquire a series of innovative technologies in the immuno-oncology space from iOncologi, Inc., (“iOi”). ...  Read more